Back
53
10
20
Also listed as
SSMXF
OTC
Day Range
$8.50
$8.55
52-Week Range
$8.15
$19.65
Volume
9,783
50D / 200D Avg
$9.30
/
$12.08
Prev Close
$8.36
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 0.1 | 0.4 |
| P/B | 0.0 | 2.9 |
| ROE % | 12.0 | 3.8 |
| Net Margin % | 10.6 | 3.9 |
| Rev Growth 5Y % | 13.6 | 10.0 |
| D/E | 0.1 | 0.2 |
Key Takeaways
Revenue grew 13.63% annually over 5 years — strong growth
ROE of 11.98% — decent returns on equity
Debt/Equity of 0.14 — conservative balance sheet
Generating 38.29B in free cash flow
P/E of 0.10 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 3.42%
Growth
Revenue Growth (5Y)
13.63%
Revenue (1Y)10.21%
Earnings (1Y)8.12%
FCF Growth (3Y)22.09%
Quality
Return on Equity
11.98%
ROIC12.43%
Net Margin10.55%
Op. Margin17.22%
Safety
Debt / Equity
0.14
Current Ratio2.97
Interest Coverage24.90
Valuation
P/E Ratio
0.10
P/B Ratio0.01
EV/EBITDA-0.22
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10.21% | Revenue Growth (3Y) | 11.31% |
| Earnings Growth (1Y) | 8.12% | Earnings Growth (3Y) | 8.27% |
| Revenue Growth (5Y) | 13.63% | Earnings Growth (5Y) | 13.89% |
| Profitability | |||
| Revenue (TTM) | 508.64B | Net Income (TTM) | 53.67B |
| ROE | 11.98% | ROA | 8.07% |
| Gross Margin | 53.47% | Operating Margin | 17.22% |
| Net Margin | 10.55% | Free Cash Flow (TTM) | 38.29B |
| ROIC | 12.43% | FCF Growth (3Y) | 22.09% |
| Safety | |||
| Debt / Equity | 0.14 | Current Ratio | 2.97 |
| Interest Coverage | 24.90 | Dividend Yield | 0.01% |
| Valuation | |||
| P/E Ratio | 0.10 | P/B Ratio | 0.01 |
| P/S Ratio | 0.01 | PEG Ratio | 3.85 |
| EV/EBITDA | -0.22 | Dividend Yield | 0.01% |
| Market Cap | 5.32B | Enterprise Value | -19.52B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 508.64B | 461.51B | 410.50B | 363.78B | 305.07B |
| Net Income | 53.67B | 49.64B | 45.78B | 44.09B | 31.90B |
| EPS (Diluted) | 86.05 | 79.24 | 72.91 | 70.16 | 50.82 |
| Gross Profit | 271.98B | 242.50B | 216.08B | 190.59B | 154.30B |
| Operating Income | 87.58B | 78.38B | 72.65B | 69.57B | 50.95B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 665.27B | 618.92B | 531.07B | 483.71B | 424.90B |
| Total Liabilities | 200.73B | 186.02B | 142.72B | 134.90B | 118.96B |
| Shareholders' Equity | 463.78B | 432.05B | 387.67B | 348.30B | 307.90B |
| Total Debt | 64.74B | 55.34B | 22.59B | 22.28B | 21.96B |
| Cash & Equivalents | 89.57B | 75.51B | 69.46B | 73.75B | 66.47B |
| Current Assets | 364.82B | 343.46B | 295.49B | 275.09B | 230.83B |
| Current Liabilities | 122.83B | 118.08B | 111.10B | 102.08B | 89.91B |
Strategy Scores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
#256 of 820
#557 of 616
#470 of 708
Recent Activity
Entered
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered
Defensive Investing (Benjamin Graham)
Mar 24, 2026